Merck (MRK) Amortizatization of Intangibles (2020 - 2026)

Merck (MRK) posted quarterly Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% YoY from $597.0 million in Q1 2025, and down 4.32% sequentially from $973.0 million in Q4 2025.

Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Merck has disclosed Amortizatization of Intangibles across 7 years of filings, most recently posting $931.0 million for Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million; the TTM figure through Mar 2026 stood at $3.1 billion (up 24.18% YoY), while the FY2025 annual figure was $2.8 billion, up 16.62% from the prior year.
  • Amortizatization of Intangibles retreated to $931.0 million in Q1 2026, from $973.0 million in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for MRK reached as high as $973.0 million in Q4 2025 and fell as low as $460.0 million in Q3 2022.
  • The 5-year median for Amortizatization of Intangibles is $597.0 million (2025), against an average of $602.8 million.
  • Annual changes were most pronounced in 2023 — Amortizatization of Intangibles declined 22.32% — and 2026, when it soared 55.95%.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then jumped by 46.1% to $675.0 million in 2024, then surged by 44.15% to $973.0 million in 2025, then decreased by 4.32% to $931.0 million in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $931.0 million, $973.0 million, and $623.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. of Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 1.70 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 931.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 596.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 107.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 931.00 Mn
Mar 31, 2026 931.00 Mn
Dec 31, 2025 973.00 Mn
Dec 31, 2025 973.00 Mn
Sep 30, 2025 623.00 Mn
Sep 30, 2025 623.00 Mn
Jun 30, 2025 601.00 Mn
Jun 30, 2025 601.00 Mn
Mar 31, 2025 597.00 Mn
Mar 31, 2025 597.00 Mn
Dec 31, 2024 675.00 Mn
Dec 31, 2024 675.00 Mn
Sep 30, 2024 633.00 Mn
Sep 30, 2024 633.00 Mn
Jun 30, 2024 614.00 Mn
Jun 30, 2024 614.00 Mn
Mar 31, 2024 473.00 Mn
Mar 31, 2024 473.00 Mn
Dec 31, 2023 462.00 Mn
Dec 31, 2023 462.00 Mn